Role of microRNAs in regulation of T17-driven airway epithelial barrier dysfunction

Author(s):  
Elisabeth Ax ◽  
Henric Olsson ◽  
Cecilia Lässer ◽  
Zala Jevnikar ◽  
Madeleine Rådinger
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Cuiping Ye ◽  
Chaowen Huang ◽  
Mengchen Zou ◽  
Yahui Hu ◽  
Lishan Luo ◽  
...  

Abstract Background The dysfunction of airway epithelial barrier is closely related to the pathogenesis of asthma. Secreted Hsp90α participates in inflammation and Hsp90 inhibitor protects endothelial dysfunction. In the current study, we aimed to explore the role of secreted Hsp90α in asthmatic airway epithelial barrier function. Methods Male BALB/c mice were sensitized and challenged with HDM to generate asthma model. The 16HBE and Hsp90α-knockdown cells were cultured and treated according to the experiment requirements. Transepithelial Electric Resistance (TEER) and permeability of epithelial layer in vitro, distribution and expression of junction proteins both in vivo and in vitro were used to evaluate the epithelial barrier function. Western Blot was used to evaluate the expression of junction proteins and phosphorylated AKT in cells and lung tissues while ELISA were used to evaluate the Hsp90α expression and cytokines release in the lung homogenate. Results HDM resulted in a dysfunction of airway epithelial barrier both in vivo and in vitro, paralleled with the increased expression and release of Hsp90α. All of which were rescued in Hsp90α-knockdown cells or co-administration of 1G6-D7. Furthermore, either 1G6-D7 or PI3K inhibitor LY294002 suppressed the significant phosphorylation of AKT, which caused by secreted and recombinant Hsp90α, resulting in the restoration of epithelial barrier function. Conclusions Secreted Hsp90α medicates HDM-induced asthmatic airway epithelial barrier dysfunction via PI3K/AKT pathway, indicating that anti-secreted Hsp90α therapy might be a potential treatment to asthma in future.


2020 ◽  
Vol 319 (3) ◽  
pp. L481-L496
Author(s):  
Carrie C. Smallcombe ◽  
Terri J. Harford ◽  
Debra T. Linfield ◽  
Susana Lechuga ◽  
Vladimir Bokun ◽  
...  

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children worldwide. While most develop a mild, self-limiting illness, some develop severe acute lower respiratory infection and persistent airway disease. Exposure to ambient particulate matter has been linked to asthma, bronchitis, and viral infection in multiple epidemiological studies. We hypothesized that coexposure to nanoparticles worsens RSV-induced airway epithelial barrier dysfunction. Bronchial epithelial cells were incubated with titanium dioxide nanoparticles (TiO2-NP) or a combination of TiO2-NP and RSV. Structure and function of epithelial cell barrier were analyzed. Viral titer and the role of reactive oxygen species (ROS) generation were evaluated. In vivo, mice were intranasally incubated with TiO2-NP, RSV, or a combination. Lungs and bronchoalveolar lavage (BAL) fluid were harvested for analysis of airway inflammation and apical junctional complex (AJC) disruption. RSV-induced AJC disruption was amplified by TiO2-NP. Nanoparticle exposure increased viral infection in epithelial cells. TiO2-NP induced generation of ROS, and pretreatment with antioxidant, N-acetylcysteine, reversed said barrier dysfunction. In vivo, RSV-induced injury and AJC disruption were augmented in the lungs of mice given TiO2-NP. Airway inflammation was exacerbated, as evidenced by increased white blood cell infiltration into the BAL, along with exaggeration of peribronchial inflammation and AJC disruption. These data demonstrate that TiO2-NP exposure exacerbates RSV-induced AJC dysfunction and increases inflammation by mechanisms involving generation of ROS. Further studies are required to determine whether NP exposure plays a role in the health disparities of asthma and other lung diseases, and why some children experience more severe airway disease with RSV infection.


Author(s):  
Jennifer Kricker ◽  
Thorarinn Gudjonsson ◽  
Ari Jon Arason ◽  
Jon Pétur Joelsson ◽  
Bryndis Valdimarsdottir ◽  
...  

2021 ◽  
Author(s):  
Yun Ji ◽  
Shuting Fang ◽  
Ying Yang ◽  
Zhenlong Wu

Abstract Background Nephrolithiasis (also known as renal stones) is a common disease condition in companion animals, including dogs and cats. Dysfunction of renal tubular epithelial cells involves in the pathogenesis of renal stones. However, a functional role of Wnt/β-catenin signaling and its contribution to nephrolithiasis remains unknown. Results In the present study, we found that Mardin-Darby canine kidney (MDCK) cells treated with sodium oxalate resulted in reduced cell proliferation and migration, which was associated with the G0/G1 phase arrest of cell cycle progression. In addition, sodium oxalate exposure led to decreased transepithelial electrical resistance (TEER) and increased paracellular permeability. The deleterious effect of sodium oxalate on epithelial barrier function was related to decreased protein abundances of claudin-1, occludin, zonula occludens (ZO)-1, ZO-2 and ZO-3. Of note, protein levels of p-β-catenin (Ser552) in MDCK cells were repressed by sodium oxalate, indicating an inhibitory effect on the Wnt/β-catenin signaling. Intriguingly, SB216763, a GSK-3β inhibitor, enhanced the expression p-β-catenin (Ser552), and protected against epithelial barrier dysfunction in sodium oxalate-treated MDCK cells. Conclusion Taken together, our results revealed a critical role of Wnt/β-catenin signaling on the epithelial barrier function of MDCK cells. Activation of Wnt/β-catenin signaling might be an potentially therapeutic target for the treatment of renal stones in animals.


2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Fang Wang ◽  
Rebecca A. Eitnier ◽  
Alexandra M. Aponte ◽  
Thomas J. Ewing ◽  
Mack H. Wu

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Miyoko Tatsuta ◽  
Keiko Kan-o ◽  
Yumiko Ishii ◽  
Norio Yamamoto ◽  
Tomohiro Ogawa ◽  
...  

Abstract Background Airway epithelial barrier function is maintained by the formation of tight junctions (TJs) and adherens junctions (AJs). Inhalation of cigarette smoke causes airway epithelial barrier dysfunction and may contribute to the pathogenesis of chronic lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). We assessed the effects of cigarette smoke on barrier function and expression of multiple TJ and AJ proteins in the bronchial epithelium. We also examined whether treatment with glucocorticosteroids (GCSs), long-acting β2-agonists (LABAs), and human cathelicidin LL-37 can protect against cigarette smoke extract (CSE)-induced barrier dysfunction. Methods Calu-3 cells cultured at the air-liquid interface were pretreated with or without GCSs, LABAs, GCSs plus LABAs, or LL-37, and subsequently exposed to CSE. Barrier function was assessed by transepithelial electronic resistance (TEER) measurements. Gene and protein expression levels of TJ and AJ proteins were analyzed by quantitative PCR and western blotting, respectively. Immunofluorescence staining of TJ and AJ proteins was performed. Results CSE decreased TEER and increased permeability in a concentration-dependent manner. CSE suppressed gene expression of claudin-1, claudin-3, claudin-4, claudin-7, claudin-15, occludin, E-cadherin, junctional adhesion molecule-A (JAM-A) and zonula occludens-1 (ZO-1) within 12 h post-CSE exposure, while suppressed protein expression levels of occludin at 12 h. CSE-treated cells exhibited discontinuous or attenuated immunostaining for claudin-1, claudin-3, claudin-4, occludin, ZO-1, and E-cadherin compared with untreated cells. GCS treatment partially restored CSE-induced TEER reduction, while LABA treatment had no effect. GCS and LABA combination treatment had no additive effect on CSE-induced TEER reduction and gene suppression of TJ and AJ proteins. Human cathelicidin LL-37 counteracted CSE-induced TEER reduction and prevented disruption of occludin and ZO-1. LL-37 also attenuated CSE-induced decreases in gene and protein expression levels of occludin. Conclusions CSE caused airway epithelial barrier dysfunction and simultaneously downregulated multiple TJ and AJ proteins. GCS and LABA combination treatment had no additive effect on CSE-induced TEER reduction. LL-37 counteracted CSE-induced TEER reduction and prevented disruption of occludin and ZO-1. Use of LL-37 to counteract airway epithelial barrier dysfunction may have significant benefits for respiratory diseases such as asthma and COPD.


Sign in / Sign up

Export Citation Format

Share Document